Literature DB >> 26025114

Properly assessing CD133 as a risk factor for poor prognosis in patients with hepatocellular carcinoma after resection.

Hao-Feng Lu1, Wei-Ping Yuan, Mi Li, Qiang Huang, Jian-Ping Liu, Le-Qun Li, Jian-Hong Zhong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26025114     DOI： 10.1007/s13277-015-3612-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


× No keyword cloud information.
  10 in total

1.  Intermediate-stage HCC--upfront resection can be feasible.

Authors:  Jian-Hong Zhong; Shi-Dong Lu; Yan-Yan Wang; Liang Ma; Le-Qun Li
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 2.  Cancer stem cells.

Authors:  Craig T Jordan; Monica L Guzman; Mark Noble
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

Review 3.  Opinion: the origin of the cancer stem cell: current controversies and new insights.

Authors:  Rolf Bjerkvig; Berit B Tysnes; Karen S Aboody; Joseph Najbauer; A J A Terzis
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

4.  An exploratory test for an excess of significant findings.

Authors:  John P A Ioannidis; Thomas A Trikalinos
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

5.  Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.

Authors:  Anthony W H Chan; Joanna H M Tong; Stephen L Chan; Paul B S Lai; Ka-Fai To
Journal:  Histopathology       Date:  2014-02-07       Impact factor: 5.087

6.  Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.

Authors:  Chen Zhong; Jin-Dao Wu; Ming-Ming Fang; Li-Yong Pu
Journal:  Tumour Biol       Date:  2015-04-29

Review 7.  Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Yu-Cheng Ma; Jia-Yin Yang; Lu-Nan Yan
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 2.566

8.  Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.

Authors:  W Song; H Li; K Tao; R Li; Z Song; Q Zhao; F Zhang; K Dou
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

9.  Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature.

Authors:  Zhenglun Pan; Thomas A Trikalinos; Fotini K Kavvoura; Joseph Lau; John P A Ioannidis
Journal:  PLoS Med       Date:  2005-11-22       Impact factor: 11.069

Review 10.  Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion.

Authors:  Jian-Hong Zhong; A Chapin Rodríguez; Yang Ke; Yan-Yan Wang; Lin Wang; Le-Qun Li
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889
  10 in total
  2 in total

1.  Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis.

Authors:  Bin Jin; Zhiwei Gong; Nongguo Yang; Zhaoquan Huang; Sien Zeng; Hui Chen; Sanyuan Hu; Guangdong Pan
Journal:  Tumour Biol       Date:  2015-11-23

2.  Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p.

Authors:  Haiyan Liu; Yan Wu; Shunye Wang; Jie Jiang; Chenlu Zhang; Yijing Jiang; Xingfeng Wang; Lewen Hong; Hongming Huang
Journal:  BMC Cancer       Date:  2019-10-10       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.